SIM0500
Phase 1Small molecule
Jiangsu Simcere Pharmaceutical Co., Ltd.SIM0500 is one of 6 small molecule programs targeting Relapsed or Refractory Multiple Myeloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Relapsed or Refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Etentamig
AbbViePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Preclinical
SG301
HHangzhou Sumgen Biotech Co., Ltd.
Phase 1
JNJ-79635322
Johnson & JohnsonPhase 1
SIM0500
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SIM0500. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details